oral semaglutide cardiovascular outcomes soul trial results 2024 2025 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Targeting the weight within: obesity

The side effect profile can differ because each peptide works through different pathways and may require different monitoring

Potential Side Effects of GLP-1 RAs (including Semaglutide, Liraglutide, Dulaglutide, and Tirzepatide) Like all medications, GLP-1 RAs and dual-action agonists can have side effects

Tirzepatide continues to be the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively) and showed the largest increase in total prescribing from September to December 2025

Carter BZ, Milella M, Tsao TY, Wathen JK, Altieri DC, Andreeff M

4 (ci 14700), d&c green no